STAT

Opinion: A view from inside MIT: The Epstein scandal is a teachable moment for colleges and universities

I'm an MIT professor. The university's entanglement with Jeffrey Epstein should force academia to take a difficult look at its own fundraising efforts.

A month after Jeffrey Epstein’s suicide in a Manhattan jail cell, the number of people infected by his amorality and deceit remains unknown. The latest high-profile casualty is Joichi “Joi” Ito, the longtime head of the Media Lab at the Massachusetts Institute of Technology, the university where I work as a professor and as the director of a graduate program in science journalism.

Instead of viewing this as an isolated incident, universities, colleges, and cultural institutions should use it as an impetus to take a difficult look at their own fundraising efforts. Refusing money from a convicted pedophile should be a no-brainer, but it’s time that the larger academic and scientific communities examine our willingness to accept money from donors whose actions directly oppose our values and missions, even if they’re not overtly criminal.

It’s worth using the still-unfolding Epstein-MIT scandal as a case study of a respected leader sullying his own reputation and damaging a revered institution for

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks